Altimmune, Inc.

97 articles with Altimmune, Inc.

• 

  Clinical Catch-Up: June 22-26

  6/29/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update

  5/13/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update.

• Altimmune to Announce First Quarter 2020 Financial Results on May 14

  5/8/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020. Conference Call Details Date:   Thursday, May 14 Time:   8:30 am Eastern Time Domestic:   855-327-6837 International:   631-891-4304 Conference ID:   10009533 W

• 

  Biopharma Update on the Novel Coronavirus: April 2

  4/2/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
• 

  Biopharma Update on the Novel Coronavirus: March 30

  3/30/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.

• Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate UpdateConference Call & Webcast Scheduled for Friday, March 27, at 8:30 am Eastern Time

  3/27/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a corporate update. “2019 was a productive year for the Company with the acquisition of ALT-801, a supplemental award for the development of NasoShield from BARDA, and the advancement of ALT-702 as a preclinical program,” said Vipin K. Garg, Ph.D., President and Chief Executive Offi

• Altimmune to Announce Year End 2019 Financial Results on March 27

  3/25/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.

• Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine

  2/28/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus.

• Altimmune to Present at Upcoming Investor and Scientific Conferences

  2/4/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:

• Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer

  1/23/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity following intra-tumoral injection in an individual solid tumor.

• Altimmune to Present at the 2020 NASH-TAG Conference

  1/7/2020

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January 9-11, 2020 in Park City, Utah. 

• Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASHConference Call & Webcast Scheduled for Thursday, December 5th at 11:00am Eastern Time

  11/21/2019

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company’s GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH), on Thursday, December 5th at 11am Eastern Time

• Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio

  7/9/2019

  Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH

• Altimmune Closes on $16.9 Million in Funding

  10/3/2018

  $12 million underwritten public offering closed October 2 $4.9 million registered direct offering closed September 26

• Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine

  9/10/2018

  A statistically superior mucosal immune response providing a first line of defense against infection

• Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.

  1/23/2018

  The Company has already been granted patents extending IP protection for intranasal administration of NasoShield in Europe and Japan.

• Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors

  1/3/2018

  The Board’s current Chairman, David Drutz, M.D., will remain on as Chairman of the Compensation Committee and Member of the Board.